Dr. Jeffrey Weber on CheckMate-064 Trial for Advanced Melanoma

Jeffrey S. Weber, MD, PhD
Published: Monday, Jun 13, 2016

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the design and results of the CheckMate-064 trial, which examined outcomes in patients who received nivolumab (Opdivo) given sequentially with ipilimumab (Yervoy) in patients with advanced melanoma.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x